Models for 10,000 Human Diseases
CRISPR Screen Identifies Potential New Regulators of Fibrosis in Human Liver Cells
In our last few liver articles, we highlighted the urgent need for new models and treatments for non-alcoholic steatohepatitis (NASH), and looked at the potential for human liver organoids to not only model disease, but also to test new drugs for safety and efficacy....
Human Liver Organoids as a New Model for Non-Alcoholic Fatty Liver Disease
The lack of approved treatments for non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatosis (NASH) is largely explained by the shortcomings of cellular models used to unravel disease mechanisms, identify and validate new drug targets, and screen...
Cell of the Month: Liver Sinusoidal Endothelial Cells
Liver sinusoidal endothelial cells (LSECs) are highly specialized liver endothelial cells that form a physical barrier between the blood and hepatocytes. They are the most abundant non-parenchymal hepatic cell population. LSECs play an important role in physiological,...
Tempo-iMG™: Architectural Strategies
Tempo-iMG™ was cited in cell.com in a study that investigated HIV-1 integration in the unexplored microglia reservoir that gives rise to continued HIV replication in infected cells. Scientists used Tempo-iMG™ human iPSC-derived microglia to determine that CTCF, an...
NASH – The Urgent Need for Better Disease Models and New Therapies
Welcome to our new mini-series about liver organoids. In Part 1, we focus on non-alcoholic steatohepatitis (NASH), a severe and prevalent form of non-alcoholic fatty liver disease for which no drugs have been approved. We look at the current treatment landscape for...
Tempo Bioscience Services
Disease Models and Assay Services
Tempo offers services and alliances based on our advanced technological platforms and a range of capabilities. Our team differentiates ourselves based on a strong commitment to innovative solutions and quality R&D for our partners.
Tempo Bioscience Support
On Demand Custom Engineered Cell Models
Tempo develops patient relevant stem cell (iPSCs) based models to support drug discovery, preclinical studies, and early-stage clinical development.